On Tuesday, Spark Therapeutics offered what it called “highly encouraging” data in hemophilia A, and Wall Street rewarded it by driving down the stock price by nearly 28 percent.
But doctors in the field say it’s far too early to count Spark out in its effort to craft a gene therapy that could leave patients free of spontaneous bleeding.
About the Author Reprints
